Collegium Pharmaceutical (COLL) Liabilities and Shareholders Equity (2014 - 2026)

Collegium Pharmaceutical has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $2.1 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 34.1% year-over-year to $2.1 billion in Q2 2026; TTM through Jun 2026 was $7.1 billion, a 8.11% increase from a year earlier, with the FY2025 full-year figure at $1.7 billion, changed 0.41% from the prior year.
• Liabilities and Shareholders Equity was $2.1 billion for Q2 2026 at Collegium Pharmaceutical, up from $1.7 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $2.1 billion in Q2 2026, with the low at $1.1 billion in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $1.4 billion, with a median of $1.2 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 92.88% in 2022, then fell 13.22% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then slipped by 2.63% to $1.1 billion in 2023, then soared by 45.51% to $1.7 billion in 2024, then decreased by 0.41% to $1.7 billion in 2025, then advanced by 28.91% to $2.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.1 billion (Q2 2026), $1.7 billion (Q1 2026), and $1.7 billion (Q4 2025), per Business Quant data.